Enlivex Therapeutics Overview
Enlivex Therapeutics (ENLV) has a ROE of 63.85%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow63.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Enlivex Therapeutics posts a ROE of 63.85%. That is above the Healthcare sector average of 20.86%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 20.86% is typical. Enlivex Therapeutics's 63.85% is higher that level. That is roughly 206.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Enlivex Therapeutics's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 63.85%; use YoY and peer views to separate noise from signal.
Context for ENLV's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 20.86%), and (3) consistency with growth and profitability. This page covers the first two; Enlivex Therapeutics's other metric pages and overview cover the third.
Judging Enlivex Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 63.85% here, then scan peer and history charts to see if the gap is persistent.
